Back to News
Market Impact: 0.3
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Source: TechCrunch
Artificial IntelligenceHealthcare & BiotechPrivate Markets & Venture
An AI biotech raised a funding round valuing the company at $2 billion. The company is testing treatments for skin conditions and for preserving weight loss after patients discontinue GLP-1 drugs, highlighting investor backing for AI-enabled drug development and obesity-treatment adjacencies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- China's AI chip blitz arms Xi with a message for Trump: 'You can't choke us off'
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Markets are rapidly coming around to the reality that the Fed has a lot more work to do
- SoftBank shares jump over 7% after $11.1 billion bond issuance to fund OpenAI bet